IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Tan Group Art Unit: 3736

Serial No.: To be assigned Examiner: To be assigned

Filed: On even date Attorney Docket No.: 10177-151

For: MEDICAL DEVICE HAVING ANTI-MICROBIAL

PROPERTIES AND A FALSE LUMEN AND METHOD

OF MAKING THE SAME

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. BOX 1450 Alexandria, Virginia 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

1.	Enclosures accompanying this Information Disclosure Statement are:				
	1a.	Ø		of all patents, publications, applications, or other information submitted for eration by the office.	
	1b.	Αl	egible c	opy of:	
				Each U.S. patent application publication and U.S. and foreign patent;	
			Ø	Each publication or that portion which caused it to be listed on the PTO-1449;	
				For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;	
				all other information or portion which caused it to be listed on the PTO-1449.	
	1c.			glish language copy of search report(s) from a counterpart foreign application International Search Report.	
	1d.		Explan	ations of relevancy (ATTACHMENT 1(d), hereto) or English language	

abstracts of the non-English language publications.

2.	$\overline{\mathbf{A}}$	This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b): Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);						
		☐ Within three months of the date of entry of the national stage as set forth in § an international application;						
		\square	Before the mailing of the first Office action on the merits;					
		□ examin	Before the mailing of a first Office action after the filing of a request for continued camination under §1.114.					
3.		This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R §1.97(b), but before the mailing date of any of a final action under C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.						
		(Check either Item 3a or 3b)						
	3a.		The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.					
	3b.		The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is: □ enclosed □ to be about the Provide & Edwards I.I.B. Denosit Account No. 16, 1150					
			to be charged to Pennie & Edmonds LLP Deposit Account No. 16-1150.					
		(Item 3b to be checked if any reference known for more than 3 months)						
4.		☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.						
	The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:							
			enclosed. to be charged to Pennie & Edmonds LLP Deposit Account No. 16-1150.					
		The Certification Statement in Item 5 below is applicable.						
5.	☐ Certification Statement (applicable if Item 3a or Item 4 is checked)							
			(Check either Item 5a or 5b)					
	5a.		In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.					

	5b.		In accordance with 37 C.F.R. §1.97(e)(2), it is certified that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was known by any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.			
6.	□ T	his ap	oplication is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).			
			(Check appropriate Items 6a, 6b and/or 6c)			
	6a.		A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.			
	6b.		Copies of publications listed on Form PTO-1449 from prior application Serial No, filed on, of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).			
	6c.		Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. , filed on , and are provided herewith.			
7. This is a Supplemental Information Disclosure Statement. (Check either Item 7a or						
	7a.		This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on			
	7b.		This Supplemental Information Disclosure Statement is timely filed within one (1) month of a PTO Notice under 37 C.F.R. §1.97(i).			
8.			rdance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to relevance of each non-English language publication is:			
			(Check Item 8a, 8b, or 8c)			
	8a.		satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.			
	8b.		set forth in the application.			
	8c.		enclosed as an attachment hereto.			
9.	The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Pennie & Edmond LLP Deposit Account No. 16-1150					

- 3 - 1471743v1

10. ☑ No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).

Respectfully submitted,

Date <u>October 15, 2003</u>

27,469

(Reg. No.)

PENNIE & EDMONDS LLP 1155 Avenue of Americas New York NY 10036-2720 (212) 790 - 9090

Enclosures

Sheet 1 of 1

Express Mail No.: **EV 335 857 392 US**

L	IST C	OF REFERENCES C (Use several sheets	PPLICANT	ATTY DOCKET N 10177-151-9 APPLICANT Tan FILING DATE On even dat	999	APPLICATION To be ass	_		
			U.S. 1	PATENT DOCUM					
*EXAMINER INITIAL	AA	DOCUMENT NUMBER 6,319,226 B1	DATE 11/20/01	NAME C		CLASS	SUBCLASS	FILING DATE SUBCLASS IF APPROPRIATE	
	AB AC	6,280,423 B1 5,567,495	08/28/01	Davey et al. Modak et al.					
	AD	5,411,550	05/02/95	Herweck et al.					
	AE	5,269,755	12/14/93	Bodicky					
	AF	5,059,186	10/22/91	Yamamoto et al.					
	AG	5,004,455	04/02/91	Greenwood et al					
		-	FOREIC	SN PATENT DOC	CUMENTS				
	DOCUMENT NUMBER			DATE COUR		CLASS	SUBCLASS	TRANSL	ATION
	AH WO 00/74743		12/14/00	PCT				YES	NO
		OTHER REFER	RENCES (In	cluding Author, Ti	tle, Date, Pertin	ent Pages,	Etc.)	· · · · · · · · · · · · · · · · · · ·	
EXAMINE	R			DATE C	CONSIDERED				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.